Testing an experimental drug OPN-6602 for advanced multiple myeloma
Treatments studied
Part of Blood & lymphatic, Cancer, Heart & circulation, Immune system & allergy clinical trials.
This trial tests an experimental oral drug called OPN-6602 for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have a confirmed diagnosis of multiple myeloma (a cancer of plasma cells in the bone marrow).
- Your myeloma has come back or stopped responding to at least 3 different prior treatments, including an immunomodulatory drug, a proteasome inhibitor, and an anti-CD38 antibody.
- You are not a candidate for or cannot tolerate other treatments that are known to help.
- Your blood counts, kidney, liver, and heart function need to be within a certain healthy range.
- You cannot have certain other conditions such as active plasma cell leukemia, POEMS syndrome, or a history of Stevens Johnson syndrome.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This clinical trial tests a combination of three drugs—mezigdomide, carfilzomib, and dexamethasone—for people with multiple myeloma that has come back or stopped responding to prior treatments, especially when the disease has spread outside the bone (extramedullary disease). It aims to see if this new cocktail can shrink tumors and control myeloma more effectively.
This trial tests a new injected drug for people with multiple myeloma that has returned or stopped responding to at least 3 prior treatments. The goal is to see if the drug is safe and works against the cancer.
This trial tests a new experimental drug called CM336 for people with multiple myeloma that has come back or stopped responding to standard treatments. The drug may work by helping your immune system attack and destroy myeloma cells. If you join, you will receive the study treatment and be closely monitored to see how well it works and how safe it is.
This trial tests a new treatment combination for multiple myeloma that has returned or stopped responding to previous therapy and has spread outside the bone marrow. It aims to see if the combination can shrink these tumors and improve outcomes.
This study tests an experimental drug called RN9101 for people with multiple myeloma that has returned or stopped responding to other treatments. The drug targets a protein called BCMA found on myeloma cells, and the goal is to see if it is safe and can help control the disease.
This trial tests a new treatment called OL-101 for people whose multiple myeloma has come back or stopped responding to at least three prior treatments, including a proteasome inhibitor, an immunomodulatory drug, and an anti-CD38 antibody. It aims to see if OL-101 can help control the disease.
Hear when a new Relapsed Multiple Myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.